Human immune organoids
The human immune
response, engineered
Antibodies raised against your target by human immune cells, in engineered synthetic hydrogels. No animal immunization. No display libraries.
What we do
OrganoAb develops a next-generation platform for human antibody discovery using proprietary human immune organoids engineered in synthetic hydrogels to replicate the immune microenvironments where antibody responses naturally develop and mature.
Antibodies are raised de novo from human donor blood cells, so new binders emerge against your target rather than being selected from a fixed library. The platform supports antibody discovery against difficult targets, and the study of responses to therapeutic candidates and vaccines.
- Human-derived antibody responses
- No animal immunization required
- No phage or synthetic display libraries
A human-first route to difficult targets
The platform is designed to generate human antibody responses to a target in a controlled, reproducible environment. Our organoids are built in engineered synthetic hydrogels that recreate key features of the tissue where B cells normally meet antigen and mature into antibody-producing cells.
Human-derived antibody responses
Antibodies come from peripheral blood mononuclear cells (PBMCs) donated by people, so responses reflect human immune biology rather than an animal host. Because blood is widely available, studies can draw on many different donors, unlike approaches that depend on tonsils or other immune tissue.
Supports germinal center formation and affinity maturation
The organoid is built to support the reactions that normally occur in germinal centers, where B cells respond to a target and their antibodies improve in affinity. This is what allows new antibodies to be raised against a target rather than selected from a fixed library.
Defined, reproducible, and tunable
The synthetic hydrogel has a defined composition, avoiding the batch-to-batch variability of animal-derived matrices such as Matrigel®, and its properties can be tuned. Culture conditions and antigen exposure are set by design, so conditions can be compared side by side.
Applications we are advancing
Antibody discovery is our lead application. Immunogenicity and vaccine studies are in development, and we discuss each with partners as a defined engagement.
Antibody discovery
De novo antibodies raised against your target by B cells in human donor PBMCs, without animal immunization or display libraries. We are advancing the platform for challenging targets, including GPCRs and other membrane proteins.
Antibody discovery details In developmentExploratory immunogenicity assessment
Human B cell studies designed to complement existing immunogenicity risk assessment methods for therapeutic candidates.
Immunogenicity details In developmentVaccine and adjuvant response profiling
Comparative human B cell responses to antigen designs and adjuvants, as an additional source of information before clinical testing.
Vaccine profiling detailsResearch collaborations
The platform also supports research in immunotoxicity and immune disease modeling. We take on this work as research collaborations rather than standard services. Tell us about your question.
The science
The platform builds on research from the laboratories of Ankur Singh and Andrés García on synthetic hydrogels that reproduce key features of human immune tissue.
Publication
Human immune organoids to decode B cell response in healthy donors and patients with lymphoma
Zhong Z, et al. Nature Materials 24, 297–311 (2025)
The study reported synthetic hydrogel organoids supporting germinal center-like responses from human tonsil and peripheral blood B cells, including germinal center compartments, somatic hypermutation, immunoglobulin class switching, and B cell clones.
News
Georgia Program Backs Pioneering Antibody Research with Global Reach
Georgia Tech Research News, May 27, 2026
A $250,000 Georgia Research Alliance Innovation and Entrepreneurship award supports Singh and García’s work to develop functional human antibodies against difficult disease targets.
Work with us
Projects are designed and coordinated by the OrganoAb team. Partners bring the molecules, targets, or questions; we bring the platform and the scientific team behind it.
Defined projects
A single discovery campaign or study, scoped with defined deliverables. A practical way to evaluate the platform on a question you care about.
Strategic partnerships
Multi-project agreements for partners who want ongoing access to the platform across a portfolio of programs.
Team
Tracey Mullen, MBA
CEO and President
Built and scaled antibody discovery businesses, including Abveris through its acquisition by Twist Bioscience.
Full bio
Tracey Mullen has spent more than 15 years in antibody discovery, first as a scientist and then building and running discovery service businesses. As CEO of Abveris, she led the company through its $190M acquisition by Twist Bioscience, then served as Senior Vice President of Operations and of Biopharma at Twist. At Biogen, she worked on antibody discovery against challenging target classes, including GPCRs and ion channels. She serves on the Board of Directors of Aeterna Therapeutics and holds a BS in Chemical and Biological Engineering from MIT and an executive MBA.
Ankur Singh, PhD
Founder and Chief Scientific Officer
Inventor of the human immune organoid platform and a leader in translational immunoengineering.
Full bio
Ankur Singh is the Carl Ring Family Professor in the Woodruff School of Mechanical Engineering at Georgia Tech, with a joint appointment in the Coulter Department of Biomedical Engineering at Georgia Tech and Emory. He directs Georgia Tech’s Center for Immunoengineering and is Deputy Director of the Petit Institute for Bioengineering and Bioscience. His laboratory develops immune organoids and enabling technologies for studying healthy and diseased immune cells. He was previously a tenured faculty member at Cornell University and is a Fellow of the American Institute for Medical and Biological Engineering.
Andrés García, PhD
Founder and Scientific Advisor
National Academy member, biomaterials pioneer, and serial entrepreneur.
Full bio
Andrés García is Executive Director of the Petit Institute for Bioengineering and Bioscience and Regents’ Professor in the Woodruff School of Mechanical Engineering at Georgia Tech. His research combines engineering, materials science, and cell biology to create cell-instructive biomaterials, and he has co-founded several start-up companies. He is an elected member of the National Academy of Engineering, the National Academy of Medicine, the National Academy of Inventors, and the American Academy of Arts and Sciences, and served as President of the Society for Biomaterials.
OrganoAb was spun out of immune organoid research at Georgia Tech.